RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations

Graham, J., Earnshaw, S., Lim, J., Luthra, R., & Borker, R. (2016). Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations. Journal of Clinical Pathways, 2(4), 31-39. http://www.journalofclinicalpathways.com/article/cost-effectiveness-afatinib-versus-erlotinib-first-line-treatment-patients-metastatic-non

Download/Explore
Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Meet the Experts

Navigate to Stephanie Earnshaw

Stephanie Earnshaw